Evidence map›Paper›PMID 26082781›Full record

ArticleFrontiers in immunology2015

Protective Potential of Antioxidant Enzymes as Vaccines for Schistosomiasis in a Non-Human Primate Model.

Claudia Carvalho-Queiroz, Ruth Nyakundi, Paul Ogongo, Hitler Rikoi, Nejat K Egilmez, Idle O Farah, Thomas M Kariuki, Philip T LoVerde

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Oxidative Stress and Cancer Risk in Schistosomiasis.Oxidative medicine and cellular longevity · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. A comprehensive and critical overview of schistosomiasis vaccine candidates.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021
    Review
  9. Article
  10. Visit to intensive care of 2050.Intensive care medicine · 2017
    Article
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Claudia Carvalho-QueirozDepartment of Biochemistry, University of Texas Health Science Center , San Antonio, TX , USA ; Department of Pathology, University of Texas Health Science Center , San Antonio, TX , USA.
Ruth NyakundiInstitute of Primate Research, National Museums of Kenya , Nairobi , Kenya.
Paul OgongoInstitute of Primate Research, National Museums of Kenya , Nairobi , Kenya.
Hitler RikoiInstitute of Primate Research, National Museums of Kenya , Nairobi , Kenya.
Nejat K EgilmezDepartment of Microbiology and Immunology, School of Medicine and Biomedical Sciences, University at Buffalo , Buffalo, NY , USA.
Idle O FarahInstitute of Primate Research, National Museums of Kenya , Nairobi , Kenya.
Thomas M KariukiInstitute of Primate Research, National Museums of Kenya , Nairobi , Kenya.
Philip T LoVerdeDepartment of Biochemistry, University of Texas Health Science Center , San Antonio, TX , USA ; Department of Pathology, University of Texas Health Science Center , San Antonio, TX , USA.
National Museums of Kenya · KEThe University of Texas Health Science Center at San Antonio · USInstitute of Primate Research · KEUniversity at Buffalo, State University of New York · US

Funding

TOWARD A MOLECULARLY-DEFINED VACCINE FOR SCHISTOSOMIASISR01AI018867 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LOVERDE, PHILIP T · 1989 to 2009
$2.7M
NIAID NIH HHS R01 AI018867
6 · The paper itself

Abstract

Schistosomiasis remains a major cause of morbidity in the world. The challenge today is not so much in the clinical management of individual patients, but rather in population-based control of transmission in endemic areas. Despite recent large-scale efforts, such as integrated control programs aimed at limiting schistosomiasis by improving education and sanitation, molluscicide treatment programs and chemotherapy with praziquantel, there has only been limited success. There is an urgent need for complementary approaches, such as vaccines. We demonstrated previously that anti-oxidant enzymes, such as Cu-Zn superoxide dismutase (SOD) and glutathione S peroxidase (GPX), when administered as DNA-based vaccines induced significant levels of protection in inbred mice, greater than the target 40% reduction in worm burden compared to controls set as a minimum by the WHO. These results led us to investigate if immunization of non-human primates with antioxidants would stimulate an immune response that could confer protection as a prelude study for human trials. Issues of vaccine toxicity and safety that were difficult to address in mice were also investigated. All baboons in the study were examined clinically throughout the study and no adverse reactions occurred to the immunization. When our outbred baboons were vaccinated with two different formulations of SOD (SmCT-SOD and SmEC-SOD) or one of GPX (SmGPX), they showed a reduction in worm number to varying degrees, when compared with the control group. More pronounced, vaccinated animals showed decreased bloody diarrhea, days of diarrhea, and egg excretion (transmission), as well as reduction of eggs in the liver tissue and in the large intestine (pathology) compared to controls. Specific IgG antibodies were present in sera after immunizations and 10 weeks after challenge infection compared to controls. Peripheral blood mononuclear cells, mesenteric, and inguinal node cells from vaccinated animals proliferated and produced high levels of cytokines and chemokines in response to crude and recombinant antigens compared with controls. All together, these data demonstrate the potential of antioxidants as a vaccine in a non-human primate model.

Indexed as

anti-fecundityantioxidantsbaboonSchistosoma mansonivaccine

Identifiers

PMID26082781
PMCPMC4451692
OpenAlexW1486368984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.